NCT00532948View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Glioma
Interventions
DRUG

capecitabine [Xeloda]

500mg/m2 po bid (starting dose)

Trial Locations (9)

15261

Pittsburgh

19104

Philadelphia

20010

Washington D.C.

27710

Durham

60614

Chicago

77030

Houston

98105

Seattle

94143-0780

San Francisco

02115-6084

Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00532948 - A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas | Biotech Hunter | Biotech Hunter